基于曲奥舒凡的预处理方案用于脐血移植受者可行且有效:一项2期多中心研究
该前瞻性多中心2期研究于2009年3月至2019年10月纳入130例接受脐血移植的血液恶性肿瘤患者,采用曲奥舒凡(TREO)、氟达拉滨和单次2 Gy全身照射预处理。123例(95%)成功植入,3年总生存率66%、无复发生存率57%、移植相关死亡率18%、复发率24%,两风险组间临床结局无显著差异。
要点
- 基于TREO的预处理方案用于脐血移植受者安全有效,可促进脐血植入并获良好临床结局。
- 123例(95%)植入,中性粒细胞恢复中位时间:低危组19天,高危组20天。
- 3年总生存率66%、无复发生存率57%、移植相关死亡率18%、复发率24%,两风险组间无显著差异。
核心结论
- 基于TREO的预处理方案用于脐血移植受者安全有效,可促进脐血植入并获良好临床结局。
研究设计与样本
- 前瞻性多中心2期研究,2009年3月至2019年10月纳入130例接受脐血移植的血液恶性肿瘤患者,按移植失败风险分为低危组(1组,n=66)和高危组(2组,n=64)。
- 预处理方案为TREO、氟达拉滨和单次2 Gy全身照射;移植物抗宿主病预防采用环孢素和吗替麦考酚酯。
- 主要终点为移植失败发生率;中位年龄45岁(范围0.6–65岁);35例(27%)既往接受过造血干细胞移植。
主要发现
- 123例(95%)成功植入,中性粒细胞恢复中位时间:1组19天,2组20天。
- 全部患者3年总生存率66%、无复发生存率57%、移植相关死亡率18%、复发率24%。
- 既往接受过造血干细胞移植的患者3年无复发生存率为48%。
- 两风险组间临床结局无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although the use of treosulfan (TREO) in conventional donor hematopoietic cell transplantation (HCT) has been extensively evaluated, its use in cord blood transplantation (CBT) for hematologic malignancies has not been reported. Between March 2009 and October 2019, 130 CBT recipients were enrolled in this prospective multicenter phase 2 study. The conditioning regimen consisted of TREO, fludarabine, and a single fraction of 2 Gy total-body irradiation. Cyclosporine and mycophenolate mofetil were used for graft-versus-host disease prophylaxis. The primary end point was incidence of graft failure (GF), and based on risk of GF, patients were classified as low risk (arm 1, n = 66) and high risk (arm 2, n = 64). The median age was 45 years (range, 0.6-65 years). Disease status included acute leukemias in first complete remission (CR; n = 56), in ≥2 CRs (n = 46), and myelodysplastic (n = 25) and myeloproliferative syndromes (n = 3). Thirty-five patients (27%) had received a prior HCT. One hundred twenty-three patients (95%) engrafted, with neutrophil recovery occurring at a median of 19 days for patients on arm 1 and 20 days for patients on arm 2. The 3-year overall survival, relapse-free survival (RFS), transplant-related mortality, and relapse for the combined groups were 66%, 57%, 18%, and 24%, respectively. Among patients who had a prior HCT, RFS at 3 years was 48%. No significant differences in clinical outcomes were seen between the 2 arms. Our results demonstrate that TREO-based conditioning for CBT recipients is safe and effective in promoting CB engraftment with favorable clinical outcomes. This trial was registered at www.clinicaltrials.gov as #NCT00796068.
引用
- Milano F, Gutman JA, Deeg HJ, et al. Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. Blood Adv. 2020. PMID: 32706891. doi:10.1182/bloodadvances.2020002222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。